SEOUL -- Samsung Biologics looks to develop a treatment for Alzheimer's disease in partnership with Taiwanese startup Aprinoia Therapeutics, as the South Korean manufacturer moves further up the value chain to attract new clients.
Aprinoia is working on an Alzheimer's treatment, with plans for clinical trials in Taiwan and Japan. The company thinks Samsung Biologics can help with the trials and the development of mass production capabilities.
